This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ROYAL ROTTER, M.D.; OVID O. MEYER, M.D.

AMA Arch Intern Med. 1951;88(3):296-309.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE FIRST synthesis of the 4-hydroxycoumarin anticoagulant No. 63, a compound chemically related to bishydroxycoumarin (dicumarol® 3,3'-methylenebis [4-hydroxycoumarin] ), was by Dr. Myoshi Ikawa in 1942 in Dr. Karl Paul Link's laboratory.¹ It is a colorless and stable product which is readily prepared in pure form, and its solubility in water is of the order of 1/100 that of bishydroxycoumarin. Chemically anticoagulant No. 63 is 2-methyl-2-methoxy-4-phenyl-5-oxodihydropyrano-(3,2-c) (1) benzopyran. In work done by Scheel2 in the mouse, rat, rabbit, and dog, attention was given not only to activity per se, as reflected by the prolongation of the 12.5% plasma-prothrombin time, but also to the time and site of appearance of visible hemorrhage and the survival time resulting from continued administration of various coumarin anticoagulants. He concluded that 4-hydroxycoumarin anticoagulant No. 63 was a strong competitor, if not an agent superior, to bishydroxycoumarin. In dogs and in human beings this anticoagulant was . . . [Full Text PDF of this Article]

Author Affiliations
With the Technical Assistance of Doris M. Kurth, R. Edith Eisenhauer, and Kathryn Rupp MADISON, WIS.

From the Department of Medicine, University of Wisconsin Medical School.

Footnotes
This study was supported in part by the Research Committee of the Graduate School from funds supplied by the Wisconsin Alumni Research Foundation.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?